Three years after striking up a Zymeworks licensing pact with an eye on challenging the status quo in HER2-positive cancers, Jazz Pharmaceuticals is seeing its vision with Ziihera come into clearer ...
On November 17, 2025, Jazz Pharmaceuticals announced that its Phase 3 HERIZON-GEA-01 trial showed Ziihera (zanidatamab-hrii) combined with chemotherapy, with or without the PD-1 inhibitor tislelizumab ...
Jazz Pharmaceuticals added its leading drug, Xyrem, to its portfolio in 2005 with the acquisition of Orphan Medical for about $123 million. This was a great price for the then newly approved drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback